Non-Alcoholic Fatty Liver Disease Adversely Affects the Glycemic Control Afforded by Sitagliptin

被引:13
作者
Iwasaki, Tomoyuki [3 ]
Tomeno, Wataru
Yoneda, Masato [1 ]
Inamori, Masahiko
Shirakawa, Jun [2 ]
Imajo, Kento
Kawashima, Keigo
Terauchi, Yasuo [2 ]
Nakajima, Atsushi
机构
[1] Yokohama City Univ, Div Gastroenterol, Grad Sch Med, Kanazawa Ku, Yokohama, Kanagawa 232, Japan
[2] Yokohama City Univ, Grad Sch Med, Div Endocrinol & Metab, Yokohama, Kanagawa 232, Japan
[3] Iwasaki Naika Clin, Yokohama, Kanagawa, Japan
关键词
NAFLD; DM; DPP-4; inhibitor; Sitagliptin; GLUCAGON-LIKE PEPTIDE-1; IN-VITRO; DEGRADATION; PREVALENCE; INHIBITOR; RECEPTOR;
D O I
10.5754/hge11689
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: Recently, high serum DPP-4 activity was found in patients with NAFLD. Therefore, the possibility of NAFLD adversely influencing the therapeutic effect afforded by DPP-4 inhibitors in type 2 diabetic patients was suggested. Methodology: A total of 20 type 2 DM patients with NAFLD and 85 type 2 DM patients without NAFLD were enrolled in the present study. The patients were administered sitagliptin at the dose of 50 mg/day for 12 weeks. Results: The change in HbA1c from the baseline following treatment with sitagliptin was -0.47% (4 weeks), -0.73% (8 weeks) and -0.88% (12 weeks) in the type 2 DM patients with NAFLD and -0.26% (4 weeks), -0.41% (8 weeks) and -0.49% (12 weeks) in type 2 DM without NAFLD. The changes in the HbA1c from the baseline after sitagliptin treatment for 8 and 12 weeks were significantly greater in type 2 DM patients with NAFLD than in type 2 DM patients without NAFLD. Conclusions: The results of this study suggest that NAFLD might adversely affect the therapeutic effect afforded by sitagliptin treatment in patients with type 2 DM. NAFLD may be an independent predictor of the effect of sitagliptin in patients with type 2 DM.
引用
收藏
页码:1522 / 1525
页数:4
相关论文
共 22 条
[1]   Gut peptides and type 2 diabetes mellitus treatment [J].
Bo Ahrén .
Current Diabetes Reports, 2003, 3 (5) :365-372
[2]  
Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO
[3]  
2-S
[4]   Nonalcoholic fatty liver disease [J].
Brunt, Elizabeth M. ;
Wong, Vincent W. -S. ;
Nobili, Valerio ;
Day, Christopher P. ;
Sookoian, Silvia ;
Maher, Jacquelyn J. ;
Bugianesi, Elisabetta ;
Sirlin, Claude B. ;
Neuschwander-Tetri, BrentA. ;
Rinella, Mary E. .
NATURE REVIEWS DISEASE PRIMERS, 2015, 1
[5]   Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase [J].
Ben-Shlomo, Shani ;
Zvibel, Isabel ;
Shnell, Mati ;
Shlomai, Amir ;
Chepurko, Elena ;
Halpern, Zamir ;
Barzilai, Nir ;
Oren, Ran ;
Fishman, Sigal .
JOURNAL OF HEPATOLOGY, 2011, 54 (06) :1214-1223
[6]   Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006 [J].
Cheung, Bernard M. Y. ;
Ong, Kwok Leung ;
Cherny, Stacey S. ;
Sham, Pak-Chung ;
Tso, Annette W. K. ;
Lam, Karen S. L. .
AMERICAN JOURNAL OF MEDICINE, 2009, 122 (05) :443-453
[7]   NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome [J].
Chitturi, S ;
Abeygunasekera, S ;
Farrell, GC ;
Holmes-Walker, J ;
Hui, JM ;
Fung, C ;
Karim, R ;
Lin, R ;
Samarasinghe, D ;
Liddle, C ;
Weltman, M ;
George, J .
HEPATOLOGY, 2002, 35 (02) :373-379
[8]   DEGRADATION OF GLUCAGON-LIKE PEPTIDE-1 BY HUMAN PLASMA IN-VITRO YIELDS AN N-TERMINALLY TRUNCATED PEPTIDE THAT IS A MAJOR ENDOGENOUS METABOLITE IN-VIVO [J].
DEACON, CF ;
JOHNSEN, AH ;
HOLST, JJ .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1995, 80 (03) :952-957
[9]   Biological actions and therapeutic potential of the glucagon-like peptides [J].
Drucker, DJ .
GASTROENTEROLOGY, 2002, 122 (02) :531-544
[10]   Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker [J].
Firneisz, Gabor ;
Varga, Timea ;
Lengyel, Gabriella ;
Feher, Janos ;
Ghyczy, Dora ;
Wichmann, Barna ;
Selmeci, Laszlo ;
Tulassay, Zsolt ;
Racz, Karoly ;
Somogyi, Aniko .
PLOS ONE, 2010, 5 (08)